Skip to content
The Kids Research Institute Australia logo
Donate

Search

The Kids researchers seek cure for devastating glioma

The Kids Research Institute Australia’s cancer researchers will use funds raised in the name of a brave three-year-old girl to launch a new assault on the devastating form of childhood cancer which took her life.

Amazing Aroha brings comfort to other sick kids

Emma White, a registered nurse, suspected for several months that something was wrong with her 7-year-old daughter Aroha, but couldn't get answers despite visiting numerous GPs.

New childhood brain tumour drugs to be tested

It is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.

Dad’s Dream Inspires Global Cancer Fight

The Global Symposium on Childhood Brain Tumours is bringing the world's premier childhood brain tumour researchers and scientists together in Perth.

Research sheds new light on childhood Leukaemia treatment

A The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.

Global Assault on Childhood Brain Tumours Gains Momentum

A report outlining key steps to tackle a common and aggressive childhood brain tumor is gaining rapid momentum after attracting international attention.

Ethan's brain cancer battle inspires research

A new research scholarship to combat childhood brain tumours will be launched tonight in honour of two year old Perth toddler Ethan Davies.

Researchers find genetic clue to cancer relapse

Cancer researchers at The Kids for Child Health Research have developed a new test that can rapidly detect the loss of genes in cancer cells.

Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future

This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years.

In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma

Ependymomas (EPN) are the third most common malignant brain cancer in children. Treatment strategies for pediatric EPN have remained unchanged over recent decades, with 10-year survival rates stagnating at just 67% for children aged 0-14 years. Moreover, a proportion of patients who survive treatment often suffer long-term neurological side effects as a result of therapy. It is evident that there is a need for safer, more effective treatments for pediatric EPN patients.